Boulevard Bio Inks ~$1.62B Licensing Deal with METiS TechBio for MTS-128

Shots: METiS TechBio has granted Boulevard worldwide development, manufacturing, and commercialization rights to MTS-128, a trispecific T-cell engager (TCE) program As per the deal, METiS TechBio will receive a $20M upfront payment & ~$1.6B in development, regulatory, & commercial milestone payments, in addition to tiered royalties on product sales MTS-128 is a trispecific T-cell engager…

ByRidhi Rastogi1 hour ago

NEWS

Antengene Inks ~$1.96B Bispecific T-Cell Engager Deal with K2 Therapeutics

Shots: Antengene has licensed ATG-106, a preclinical CDH6×CD3 bispecific T-cell engager for solid tumors, to K2 Therapeutics & granted an option for exclusive rights to a second undisclosed bispecific TCE candidate, covering all global markets excl. Greater China As per the licensing deal, Antengene will receive $20M in upfront & near-term consideration, incl. cash &…

ByRidhi RastogiJune 23, 2026

INSIGHTS+

EMA Marketing Authorization of New Drugs in March 2026

Shots: The European Medicines Agency advanced multiple new drug approvals and late-stage recommendations in March 2026, spanning oncology, immunology, rare diseases, and women’s health, with key decisions involving Pharming, Immedica, Amgen, Gedeon Richter, UCB, and Sanofi The Committee for Medicinal Products for Human Use issued positive opinions for innovative therapies, including leniolisib (Joenja) for APDS, lurbinectedin + atezolizumab…

ByDipanshu DixitApril 21, 2026

NEWS

Kali Therapeutics Partners with Sanofi for KT501 in a ~$1.2B Deal

Shots: Kali Therapeutics has entered into a license agreement with Sanofi for KT501 to treat a broad range of B cell-mediated autoimmune diseases As per the deal, Sanofi will obtain exclusive worldwide rights to KT501, while Kali will receive upfront & near-term payments totaling $180M and up to $1.05B in development & commercial milestones, with tiered royalties…

ByRidhi RastogiMarch 23, 2026

NEWS

Astellas Partners with Vir Biotechnology for VIR-5500 in ~$1.7B Deal

Shots: Astellas has partnered with Vir Biotechnology to advance VIR-5500, a PRO-XTEN dual-masked CD3 T-cell engager targeting PSMA, for the treatment of prostate cancer As per the deal, Astellas will fund 60% & Vir 40% of global development costs; Vir will continue the P-I trial until transition, after which Astellas will assume development. Also, Vir will…

ByRidhi RastogiFebruary 24, 2026

NEWS

J&J Reports P-III Trial Outcomes Showing Tecvayli Monotherapy Extends PFS and OS in R/R Multiple Myeloma

Shots: J&J has reported positive topline Phase III (MajesTEC-9) results demonstrating that Tecvayli (teclistamab) monotx. significantly outperformed SoC in r/r multiple myeloma The study included patients with 1–3 prior therapies, all previously treated with anti-CD38 antibodies and lenalidomide. Most patients were refractory to anti-CD38 mAbs (85%), lenalidomide (79%), and their last therapy (>90%). Tecvayli achieved…

ByDipanshu DixitJanuary 15, 2026

Boulevard Bio Inks ~$1.62B Licensing Deal with METiS TechBio for MTS-128

Antengene Inks ~$1.96B Bispecific T-Cell Engager Deal with K2 Therapeutics

EMA Marketing Authorization of New Drugs in March 2026

Kali Therapeutics Partners with Sanofi for KT501 in a ~$1.2B Deal

Astellas Partners with Vir Biotechnology for VIR-5500 in ~$1.7B Deal

J&J Reports P-III Trial Outcomes Showing Tecvayli Monotherapy Extends PFS and OS in R/R Multiple Myeloma

Contact US

FOLLOW US